II. Indications
- Peptic Ulcer Disease
 - Esophageal Reflux disease
 - Gastritis
 - Allergic Reaction (adjunct)
 
III. Mechanism
- See H2 Blocker
 
IV. Dosing
- Adult
- Removed from U.S. market in 2020 due to NDMA contaminant (see adverse effects below)
 - Bolus IV Dosing: 50 mg IV every 6 to 8 hours
 - Continuous IV Dosing: 6.25 mg/hour IV
 - Oral Dosing: 150 mg orally twice daily
 
 - Child (15 mg/ml oral syrup)
- Removed from U.S. market in 2020 due to NDMA contaminant (see adverse effects below)
 - Age <16 years old
- Dose: 5-10 mg/kg/day (max 300 mg) divided every 12 hours
 
 - Adult dosing for over age 16 years old
- Dose: 150 mg twice daily
 
 
 - 
                          Creatinine Clearance <50 ml/min
- Give at half dose
 
 
V. Efficacy
- See H2 Blocker
 
VI. Adverse Effects
- See H2 Blocker
 - Ranitidine (Zantac) was removed from U.S. market in 2020 due to NDMA contaminant
- NDMA has been associated with several cancers
 - NDMA was found both as a manufacturing contaminant
 - NDMA also appears to form in vivo with Ranitidine use
- Resulted in the complete withdrawal of Ranitidine from U.S. market
 - In-vivo NDMA formation does not appear to occur with other H2 Blockers
 
 - FDA Recall Information
 
 - IV Ranitidine associated adverse effects
- Alanine Aminotransferase (ALT) increase
- Associated with prolonged (>5 days), high dose IV use
 
 - Bradycardia
- Associated with rapid IV administration
 
 
 - Alanine Aminotransferase (ALT) increase
 
VII. Drug Interactions
- 
                          Antacids
- Take Cimetidine at least 1-2 hours before or after Antacid medications
 
 - Decreases absorption of other medications
 - 
                          Warfarin
                          
- May affect drug levels
 
 
VIII. Safety
- Pregnancy Category B
 - Unknown safety in Lactation
 
IX. Resources
X. References
- (2012) Presc Lett, 19(7): 38
 - Baird (2015) Am Fam Physician 92(8): 705-14 [PubMed]